Figure 4. Estimated Effects of Genetic Variation in Antidiabetic Drug Targets on Alzheimer Disease and Results From the Sensitivity Analysis Using a GWAS Dataset Comprising 24,087 Clinically Diagnosed Late-Onset AD Cases and Clumping the cis-Variants With R2 From 0.001 to 0.50.

The numbers below the x axis are the value of R², and the numbers above the x axis are the number of IVs after clumping with the corresponding R². AD = Alzheimer disease; GLP-1 analogues = glucagon-like peptide 1 analogues; GWAS = genome-wide association study; IVs = instrumental variables; OR = odds ratio.